Introduction
Dopamine (DA) is a catecholamine neurotransmitter that modulates neuronal activity in several brain regions and functional networks. The basal ganglia receive strong dopaminergic input from the substantia nigra. By influencing glutamatergic neurotransmission in basal ganglia-cortex circuits, DA indirectly modulates cortical activity in primary motor cortex (M1) and other regions (Alexander et al., 1986) . In addition, cortical activity is directly modulated by dopaminergic projections from brainstem monoamine areas, mainly the ventral tegmental area (VTA) that project to cortex. For the prefrontal cortex (PFC), this direct projection is well characterized and its effects on network activity and behavior are known-including its role for motor function (Del Arco and Mora, 2008; Heijtz et al., 2007) . Unknown are the effects of a dopaminergic projection to primary motor cortex, although this projection has been well identified anatomically. It has been speculated that both direct and indirect effects of DA on M1 play a Brainstem monoamine areas such as the ventral tegmental area (VTA) send dopaminergic projections to the cerebral cortex that are widely distributed across different cortical regions. Whereas the projection to prefrontal areas (PFC) has been studied in detail, little is known about dopaminergic projections to primary motor cortex (M1). These projections have been anatomically characterized in rat and primate M1. Primates have even denser dopaminergic projections to M1 than rats. The physiological role, the effects of dopaminergic input on the activity of M1 circuits, and the behavioral function of this projection are unknown. This review explores the existing anatomical, electrophysiological and behavioral evidence on dopaminergic projections to M1 and speculates about its functional role. The projection may explain basic features of motor learning and memory phenomena. It is of clinical interest because of its potential for augmenting motor recovery after a brain lesion as well as for understanding the symptomatology of patients with Parkinson's disease. Therefore, targeted investigations are necessary.
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